Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
A phase 1/2 trial of Brenetafusp, Pembrolizumab, Tebentafusp and Bevacizumab in advanced solid tumours, run by Immunocore Ltd, active and no longer recruiting.
Overview
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors is a phase 1/2 interventional study registered as NCT04262466 by Immunocore Ltd, with 410 participants enrolled, started 2020-02-25 and due to reach its primary completion in 2026-10. Interventions recorded: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp and Brenetafusp and bevacizumab.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Shares Immunocore, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.